Androgen-deprivation therapy for prostate cancer, using anti-androgenetic drugs such as flutamide or bicalutamide, as well as castration, can lead to AR up-regulation or amplification and hypersensitization [57]. This evidence concerns the gene AR and prostate carcinoma.